Science Life: Research and Discoveries

MOMENTUM 3: Heart failure patients with HeartMate 3 have fewer blood-related adverse events than those with HeartMate II

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than patients implanted with the control, HeartMate II LVAS. In this randomized, non-blinded study, a multi-institutional team found that 69 percent of the 151 patients who received Abbott's Heartmate 3 survived without any bleeding or clotting-related adverse events, compared to 55 percent of those who received the Heartmate II.

Motivating a malignant immune system

After failed chemotherapy treatments, leukemia patient Andrew Parker participated in a CAR-T Cell clinical trial at the University of Chicago Medicine.